October 2022, Diabetis, Lithuania

/in /by

October 2022, Diabetis, Lithuania, (https://feetsee.us/) announced that it received the ‘Lithuanian-American Innovation Award 2022’, awarded jointly by the Baltic-American Freedom Foundation (BAFF), the U.S. Embassy in Lithuania, and the Innovation Agency of Lithuania. The award recognizes visionaries of the Lithuanian tech and entrepreneurial community for developing cutting-edge technologies in collaborations with U.S. partners. This year Diabetis, with its FDA-registered device ‘Feetsee’ – a self-monitoring, non-contact device for people at risk of diabetic foot ulcers – received 1st prize in this highly competitive award. The announcement can be accessed here. Congratulations to team Diabetis!

February 2022, Rezztek, Slovakia

/in /by

February 2022, Rezztek, Slovakia, (https://rezztek.com), announced that players from 7 different teams (out of a total of 12 teams) participating in the 2022 Olympics in Beijing, used Rezzteck hockey tape throughout the tournament including the gold and bronze metal games. Previously, Rezztek had announced an exclusive retail partnership with the largest US hockey retailer ‘Pure Hockey’ (https://www.purehockey.com) to distribute its patented hockey tape through Pure Hockey’s 50+ US retail (and on-line) stores. Rezztek’s multi-layered material structure allows the product to be 50% lighter than traditional hockey tape, while providing superior grip and better control of the puck. Prior to this announced partnership, Rezztek’s hockey tapes – already widely used by NHL players – were only available to professional hockey players. Congratulations team Rezztek!

January 2022, Disior Oy, Finland

/in /by

January 2022, Disior Oy, Finland, (https://www.disior.com), announced its acquisition by Colorado-based company Paragon 28, (https://paragon28.com), NYSE FNA). Disior is a 3D imaging company that develops analytics software for clinicians to better diagnose and develop patient-specific plans for complex orthopedic surgeries with focus on foot & ankle, hand & wrist as well as CMF orbital fractures. Terms of the transaction were not disclosed. Congratulations to team Disior!

October 2021, Theras Lifetech, Italy

/in /by

October 2021, Theras Lifetech, Italy, (https://www.theras-group.com/en/), announced a partner- and sponsorship agreement with MassChallenge’s HealthTech Program, making Theras the first non-US commercial partner of this program. That partnership will allow Theras access to next generation leaders in digital health, boosting the company’s own innovation initiatives and elevating its brand internationally. Theras Group’s mission is to support healthcare professionals by developing and commercializing high-tech medical devices with primary focus on chronic disease management such as diabetes and pain management.

June 2021, Aiforia, Finland

/in /by

June 2021, Aiforia, Finland, (https://www.aiforia.com), announced that it raised 12.6M euro in series B funding to enhance precision diagnostics and preclinical analysis in pathology. Aiforia is a leading provider of AI-based deep learning software solutions for clinical and preclinical image analysis in pathology across a variety of fields, from oncology to neuroscience. The company’s cloud-based software has more than 3,000 users in 50+ countries. Aiforia had previously announced that it had secured a US patent for their high-speed AI training tool in medical image analysis. Aiforia is headquartered in Helsinki, Finland and has its North American office in Cambridge, Massachusetts.

May 2021, AcceXible, Spain

/in /by

May 2021, AcceXible, Spain, (https://www.accexible.com), announced that it is entering a collaboration agreement with pharmaceutical company Eli Lilly to pilot-test the company’s vocal bio-marker platform that is able to detect and monitor early-stage dementia and other cognitive impairments with accuracy levels of higher than 90%. AcceXible is already working with NHS in the UK and recently received an innovation award from the UK’s Department of International Trade.

February 2021, Diabetis, Lithuania

/in /by

February 2021, Diabetis, Lithuania, (https://www.diabetis.lt), had a recent study published: “Algorithm for Automated Foot Detection in Thermal and Optical Images for Temperature Asymmetry Analysis.” The study can be accessed here: https://www.mdpi.com/2079-9292/10/5/571. The company, focused on solutions for diabetic ulcers, developed a non-contact device for self-monitoring of feet and identifying inflammation at an early stage. People with diabetes face a higher risk of developing foot ulcers due to neuropathy and ischemia, a complication that affects about 10 percent of diabetes patients. If left untreated, foot ulcers can lead to amputation. The company is currently conducting clinical trials for its device.

February 2021, Qompium, Belgium

/in /by

February 2021, Qompium, Belgium, a pioneering digital health company with business units Fibricheck (https://www.fibricheck.com)  and Extra Horizon (https://www.extrahorizon.com/en-us/home), raised an additional 9 million euro in venture funding. FibriCheck is a medical app that lets people monitor their heart rhythm and thereby detect hidden heart rhythm disorders such as atrial fibrillation (AF). It is the world’s first CE and FDA approved medical smartphone app for heart rhythm disorders using a camera signal. Extra Horizon is a platform that enables medical applications to go to market with far greater speed and scalability, by providing the entire backend or technical framework of such applications.

January 2021, Attention Insight, Lithuania

/in /by

January 2021, Attention Insight, Lithuania, (https://attentioninsight.com), secured new funding from Lithuanian and Polish venture capital funds which follows earlier investments last Fall. The company, which is developing an AI-powered analytics platform for website and ad-campaign pre-launch design testing, helps users automatically detect which design elements, found on websites, outdoor adverts, or other environments attract users’ highest attention. The company’s product analyses the imagery, and offers recommendations based on a database of more than 30,000 images assessed in eye-tracking studies.